Expression and correlation of sodium/iodide symporter and thyroid stimulating hormone receptor in human thyroid carcinoma

Zhi-Feng Wang¹, Qin-Jiang Liu², Shi-Qi Liao³, Rong Yang⁴, Ting Ge³, Xin He⁴, Cai-Ping Tian³, and Wei Liu⁴

¹Institute of Cell Biology, College of Life Sciences, Lanzhou University, Lanzhou Gansu; ²Department of Head and Neck Surgery, ³Molecular Biology Center, and ⁴Department of Pathology, Gansu Tumor Hospital, Lanzhou Gansu, China

ABSTRACT

Aims. To investigate the expression of sodium/iodide symporter (NIS) and thyroid stimulating hormone receptor (TSHR) in human thyroid cancer.

Patients and methods. NIS and TSHR mRNA levels quantified by real-time PCR as well as NIS and TSHR proteins evaluated by immunohistochemistry were examined in surgical specimens including 38 benign nodules, 32 thyroid carcinomas and 36 normal thyroid samples.

Results. NIS and TSHR mRNA levels in thyroid carcinomas were significantly lower than in benign nodules and normal thyroid samples (P <0.001). Interestingly, we found that NIS and TSHR mRNA expression in benign nodules had similar levels to those in normal thyroid tissues. However, NIS and TSHR protein expression in benign nodules and thyroid carcinomas was stronger than in normal thyroid samples (P <0.05) but mainly located in cytoplasm. In addition, there was a significant positive correlation between NIS and TSHR in benign nodules and normal thyroid samples (r = 0.551 and 0.667, respectively, P = 0.001 and 0.000, respectively) but there was no such correlation in thyroid carcinomas (r = 0.222, P = 0.376).

Conclusions. In thyroid carcinomas, NIS and TSHR mRNA levels were lower but the proteins were overexpressed. The NIS protein mainly locates in the cytoplasm, which therefore lacks the ability of transporting and absorbing iodine in patients with thyroid carcinoma. In addition, there was no correlation between NIS and TSHR in thyroid cancer, which may explain why, even after TSH stimulation, 10-20% of these malignant tumors are unable to concentrate enough radioiodine for effective therapy.

Key words: sodium/iodide symporter, thyroid stimulating hormone receptor, thyroid carcinoma.

Acknowledgments: This work was supported by the Gansu Science and Technology support program (No. 0804NKCA087). We thank the doctors and nurses of the department of head and neck surgery and the operating room in Gansu Tumor Hospital for their generous assistance.

Correspondence to: Qin-Jiang Liu, Gansu Tumor Hospital, Xiaoxihu ES, Lanzhou, 730050 Gansu, PR China. Tel +86-931-2614521-2010; fax +86-931-2614551; e-mail LIUQJ99@hotmail.com

Received August 30, 2010; accepted December 6, 2010.